• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
France Pharmaceuticals and Healthcare Report Q3 2008 - Product Image

France Pharmaceuticals and Healthcare Report Q3 2008

  • ID: 655927
  • September 2008
  • Region: France
  • 74 Pages
  • Business Monitor International


  • GlaxoSmithKline (GSK)
  • Ipsen
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Our France Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on France's pharmaceuticals and healthcare industry.

The French pharmaceutical market is one of the most advanced in the world but has been experiencing solid growth in recent years. The author expects this to continue over the forecast period – despite government efforts at cost containment – which is a testament to the country’s continuing high consumption levels.

Up to 2012, nominal growth should be around the 3.5% per year, comfortably outpacing inflation. France is also the largest drug producer in Western Europe and a hub for R&D research, although both of these attributes are threatened by a growing trend towards outsourcing.

The biggest change this quarter has been the continuing liberalisation of the OTC sector. Regulatory changes are to allow some 200 non-prescription drugs to be sold in front of the counter, despite complaints from pharmacies that this could cause stiff price competition. The authorities are still resisting calls to allow the sales of self-medication products in non-pharmacy outlets such as supermarkets, despite READ MORE >


  • GlaxoSmithKline (GSK)
  • Ipsen
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Executive Summary
France Pharmaceuticals And Healthcare Industry SWOT
France Political SWOT
France Economic SWOT
Pharmaceutical Business Environment Ratings
Risks To Realisation Of Returns
Table: Western Europe Pharmaceutical Business Environment Rankings
France – Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Industry Developments
Healthcare Sector
Public Health Issues
Domestic Industry
Foreign Companies
Product Approvals
Research And Development Sector
Biotechnology Sector
Table: New French Taxes On Private-Sector Research Applications
Parallel Trade
Table: First Parallel Imports In France
Clinical Research
Pharmacy Sector
Wholesale Sector
Generics Sector
Industry Forecast Scenario
Overall Market Forecast
Table: France Drug Market Expenditure Forecast Indicators
Key Factors – Industry
Table: France’s Health Expenditure Indicators, 2005-2012 45
Key Growth Factors – Macroeconomic
Table: France - Macroeconomic Forecasts
Patented Market Forecast
Table: France Patented Drugs Market Forecast Indicators (US$mn unless otherwise stated)
OTC Market Forecast
Table: France OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated)
Generics Market Forecasts
Table: France’s Generics Market Indicators
Export/Import Forecasts
Table: Sectoral Trade Indicators (US$mn)
Other Healthcare Data And Forecasts
Table: Socio-Demographic Indicators
Key Risks To Our Forecasts
Company Profiles
Leading Multinational Manufacturers
GlaxoSmithKline (GSK)
Merck & Co
Major Indigenous Companies
Our Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

- GlaxoSmithKline (GSK)
- Ipsen
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis
- Servier

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos